Project Grant R03CA304041
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$162K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This federal Project Grant award of $589,838.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Johns Hopkins University. The grant supports research to optimize an active mutant KRAS peptide vaccine for the treatment of colorectal cancer (CRC), which is the second leading cause of cancer-related mortality in the U.S. The research aims to develop improved methods for cancer treatment and increase cure rates for CRC patients....
This Project Grant award of $356,850 from the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) supports a research project at the Medical College of Wisconsin to investigate the use of EGFR inhibitors in colorectal cancer patients with mutant RAS genes. The key objectives are to: 1) Conduct functional mechanistic studies to test RAS mutants and their ability to bind the NF1 tumor suppressor for EGFR inhibitor sensitivity; 2) Pharmacologically target wild-type RAS in...
The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Targeting the Evolving Immunopeptidome of Metastatic Colorectal Cancer," aims to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic lesion patient-derived organoids (PDOs) through mass spectrometry. This will identify conserved...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $269,280 to Cold Spring Harbor Laboratory to conduct research on a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The research aims to develop prodrug molecules that can selectively degrade the K-RAS(G12C) oncogenic protein while simultaneously releasing cytotoxic natural products to target multiple cancer pathways. Key objectives include determining the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...
The National Cancer Institute (NCI) awarded a $439,367 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division. The grant, titled "Assessment of Strategies for Targeting Transcriptional Co-Activators in Colorectal Cancer," aims to investigate the role of PGC-1 family proteins, specifically PGC-1B, in promoting the survival of colorectal...
This Project Grant award, totaling $482,236 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a new targeted therapy for patients with HER2-low metastatic colorectal cancer (mCRC). The principal investigator at the Sloan-Kettering Institute for Cancer Research will conduct a Phase 2 clinical trial to evaluate the safety and efficacy of combining the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) with the...
This $657,776 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The award will fund comprehensive characterization and evaluation of this novel agent's anti-tumor activity using a wide range of tumor models. The objective is to develop a tumor-selective, safe, and highly potent pan-RAS inactivator that has high clinical utility for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611.00 to the University of Texas Health Science Center at Houston to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives are to: Characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids. Develop and evaluate highly potent GPR56-targeted...